|
| |
Image Results
Loading...
Loading...
ELIGARD Pages on BioPortfolio:
Results from other life science and pharmaceutical sites:
FDA Approvals: Prialt, Clolar, Nasonex, Eligard
30 Dec 2004 ... The FDA has approved ziconotide intrathecal infusion (Prialt), clofarabine ( Clolar), a new indication for mometasone furoate monohydrate ...
http://www.medscape.com/viewarticle/496731...
|
Eligard: leuprolide acetate in a novel sustained-release delivery ...
This review focuses on new data on a novel formulation of leuprolide acetate ( Eligard; Atrix Laboratories Inc., Fort Collins, CO) that incorporates a unique ...
http://www.ncbi.nlm.nih.gov/pubmed/12667884...
|
International Drug Approvals: Pegasys, Advate, Eligard, Mimpara
28 Dec 2004 ... Swissmedic has approved pegylated interferon alfa-2a (Pegasys) for use in Switzerland; the European Commission (EC) has approved an expanded ...
http://www.medscape.com/viewarticle/496686...
|
{1} Release: Eligard(R) Prostate Cancer Products Receive Approval ...
"We continue to make great progress in making Eligard available around the world as a new choice in hormone therapy for men with advanced prostate cancer," ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1466732...
|
ELIGARD (Leuprolide Acetate) Kit [Sanofi-Aventis US LLC - DailyMed ...
ELIGARD® is a sterile polymeric matrix formulation of leuprolide acetate for subcutaneous injection. It is designed to deliver leuprolide acetate at a ...
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=13708...
|
{1} Updates Eligard Prostate Cancer Products In Latin America ...
Eligard 7.5mg (leuprolide acetate for injectable suspension) one-month prostate cancer product was launched in May. Eligard(R) 7.5mg and 22.5mg (leuprolide ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1633812...
|
Systemic allergic dermatitis caused by the solvent of Eligard.
Systemic allergic dermatitis caused by the solvent of Eligard. Ruiz-Hornillos J, Henríquez-Santana A, Moreno-Fernández A, González IG, Sánchez SR. ...
http://www.ncbi.nlm.nih.gov/pubmed/20059500...
|
Leuprolide: Drug Information Provided by Lexi-Comp: Merck Manual ...
Eligard®: 7.5 mg monthly or 22.5 mg every 3 months or 30 mg every 4 months ... Eligard®: Vary injection site; choose site with adequate subcutaneous tissue ...
http://www.merck.com/mmpe/lexicomp/leuprolide.html...
|
Eligard. Tiny implant fights prostate cancer.
Eligard. Tiny implant fights prostate cancer. [No authors listed]. PMID: 12035639 [PubMed - indexed for MEDLINE]. Publication Types: News. Mesh Terms: ...
http://www.ncbi.nlm.nih.gov/pubmed/12035639...
|
Leuprolide - Wikipedia, the free encyclopedia
Eligard (7.5 mg for monthly subcutaneous depot injection) was first approved by the FDA for palliative treatment of advanced prostate cancer on January 24, ...
http://en.wikipedia.org/wiki/Leuprolide...
|
|